The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients

The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients

This work was supported by the Department of Dermatology at the Icahn School of Medicine at Mount Sinai and a grant from Regeneron and Sanofi. All funding sources reviewed and accepted the study design and the manuscript, with minimal input from Regeneron and Sanofi. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U01AI152036. Paolo Cravedi was supported by a grant from the National Institute of Allergy and Infectious Diseases under Award Number 3U01AI063594-17S1.

Saved in:
Bibliographic Details
Main Authors: Ungar, Benjamin, Hartzell, Susan, Lozano-Ojalvo, Daniel, Ghalili, Sabrina, Bose, Swaroop, Golant, Alexandra K., Tan, Kathryn, Estrada, Yeriel D., Singer, Giselle K., Pavel, Ana B., Cravedi, Paolo, Guttman-Yassky, Emma
Other Authors: Icahn School of Medicine at Mount Sinai
Format: carta al director biblioteca
Language:English
Published: Wiley-VCH 2023
Online Access:http://hdl.handle.net/10261/309582
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This work was supported by the Department of Dermatology at the Icahn School of Medicine at Mount Sinai and a grant from Regeneron and Sanofi. All funding sources reviewed and accepted the study design and the manuscript, with minimal input from Regeneron and Sanofi. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U01AI152036. Paolo Cravedi was supported by a grant from the National Institute of Allergy and Infectious Diseases under Award Number 3U01AI063594-17S1.

Similar Items